Vectura Group (LON:VEC) had its price objective cut by analysts at Peel Hunt from GBX 160 ($2.21) to GBX 120 ($1.66) in a report released on Wednesday. The brokerage currently has a “hold” rating on the stock. Peel Hunt’s target price would indicate a potential upside of 53.65% from the company’s previous close.

Several other research analysts have also commented on the company. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Vectura Group in a report on Thursday, January 25th. Numis Securities reiterated a “buy” rating and set a GBX 170 ($2.35) price target on shares of Vectura Group in a report on Thursday, January 4th. Shore Capital reiterated a “buy” rating on shares of Vectura Group in a report on Thursday, January 4th. Royal Bank of Canada upgraded Vectura Group to a “sector performer” rating and set a GBX 119 ($1.64) price target on the stock in a report on Thursday, December 14th. Finally, Panmure Gordon reiterated a “buy” rating and set a GBX 150 ($2.07) price target on shares of Vectura Group in a report on Thursday, November 9th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Vectura Group currently has a consensus rating of “Buy” and an average price target of GBX 169.56 ($2.34).

Vectura Group (LON VEC) opened at GBX 78.10 ($1.08) on Wednesday. Vectura Group has a fifty-two week low of GBX 77.30 ($1.07) and a fifty-two week high of GBX 166.97 ($2.31).

ILLEGAL ACTIVITY NOTICE: This report was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://theolympiareport.com/2018/02/14/peel-hunt-lowers-vectura-group-vec-price-target-to-gbx-120.html.

Vectura Group Company Profile

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Analyst Recommendations for Vectura Group (LON:VEC)

Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.